drugset / Trial / NCT04352595
A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Assess Hemay808 concentration of 1%/3%/7% for treatment of mild and moderate adult atopic dermatitis patients.
Timeline
- Start
- 2020-04-24
- Primary completion
- 2021-02-28
- Completion
- 2021-04-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hemay028 | Small molecule | 1 % | Topical |
| Subject | Hemay028 | Small molecule | 3 % | Topical |
| Subject | Hemay028 | Small molecule | 7 % | Topical |